Drugs / Pozanicline
Pozanicline
Trials 10
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 210 trials · 1 met primary · 4 missed | ||||||
| Phase 2 | NCT00809510 | Jan → Jun 2009 | Alzheimer disease | Abbott | Terminated | No outcome recorded |
| Phase 2 | NCT00686933 | May → Oct 2008 | attention deficit-hyperactivity disorder | AbbVie | Completed | No outcome recorded |
| Phase 2 | NCT00640185 | Mar → Aug 2008 | attention deficit-hyperactivity disorder | AbbVie | Completed | Missed primary |
| Phase 2 | NCT00640419 | Mar → Jul 2008 | attention deficit-hyperactivity disorder | AbbVie | Completed | Missed primary |
| Phase 2 | NCT00554385 | Nov 2007 → Aug 2008 | attention deficit-hyperactivity disorder | Abbott | Terminated | No outcome recorded |
| Phase 2 | NCT00555204 | Nov 2007 → Jun 2009 | Alzheimer disease | Abbott | Terminated | Missed primary |
| Phase 2 | NCT00528697 | Sep 2007 → Apr 2008 | attention deficit-hyperactivity disorder | AbbVie | Completed | Missed primary |
| Phase 2 | NCT00443391 | Feb 2007 → Oct 2008 | attention deficit-hyperactivity disorder | AbbVie | Completed | No outcome recorded |
| Phase 2 | NCT00391729 | Oct 2006 → Jun 2007 | attention deficit-hyperactivity disorder | Abbott | Completed | Met primary |
| Phase 2 | NCT00069849 | Jul 2003 → ? | Alzheimer disease | Abbott | Terminated | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT01756053 Comparator | Mar 2013 → Jan 2014 | nicotine dependence | University of Pennsylvania | Terminated | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 13 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pozanicline | “Pozanicline” NCT01756053 ↗ |
| Known as | A-87089.0 | ChEMBL registry synonym — accepted as the source's own label CHEMBL127071 ↗ |
| Known as | A-87089.74 | ChEMBL registry synonym — accepted as the source's own label CHEMBL127071 ↗ |
| Known as | ABT-089 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00686933 ↗ |
| Known as | Pozaniclina | ChEMBL registry synonym — accepted as the source's own label CHEMBL127071 ↗ |
| Known as | POZANICLINE TARTRATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL127071 ↗ |
| Action | Activate | “the α(4)β(2) NNR partial agonist ABT-089 versus placebo in adults with ADHD” PMID 21748252 ↗ Jul 2011 |
| Modality | Small molecule | — CHEMBL127071 ↗ |
| Route | Oral | “Subjects will take up to two 40 mg tablets once daily for 8 weeks.” NCT00640185 ↗ |